Ochalek J - Search Results

1

Informing a cost-effectiveness threshold for Saudi Arabia.

Al-Jedai AH, Lomas J, Almudaiheem HY, Al-Ruthia YSH, Alghamdi S, Awad N, Alghamdi A, Alowairdhi MA, Alabdulkarim H, Almadi M, Bunyan RF, Ochalek J. Al-Jedai AH, et al. Among authors: ochalek j. J Med Econ. 2023 Jan-Dec;26(1):128-138. doi: 10.1080/13696998.2022.2157141. J Med Econ. 2023. PMID: 36576804 Free article.

2

Estimating health opportunity costs in low-income and middle-income countries: a novel approach and evidence from cross-country data.

Ochalek J, Lomas J, Claxton K. Ochalek J, et al. BMJ Glob Health. 2018 Nov 5;3(6):e000964. doi: 10.1136/bmjgh-2018-000964. eCollection 2018. BMJ Glob Health. 2018. PMID: 30483412 Free PMC article.

3

Reflecting the Health Opportunity Costs of Funding Decisions Within Value Frameworks: Initial Estimates and the Need for Further Research.

Ochalek J, Lomas J. Ochalek J, et al. Clin Ther. 2020 Jan;42(1):44-59.e2. doi: 10.1016/j.clinthera.2019.12.002. Epub 2020 Jan 16. Clin Ther. 2020. PMID: 31955967

4

Informing a Cost-Effectiveness Threshold for Health Technology Assessment in China: A Marginal Productivity Approach.

Ochalek J, Wang H, Gu Y, Lomas J, Cutler H, Jin C. Ochalek J, et al. Pharmacoeconomics. 2020 Dec;38(12):1319-1331. doi: 10.1007/s40273-020-00954-y. Pharmacoeconomics. 2020. PMID: 32856280

5

Valuing health outcomes: developing better defaults based on health opportunity costs.

Ochalek J, Claxton K, Lomas J, Thompson KM. Ochalek J, et al. Expert Rev Pharmacoecon Outcomes Res. 2021 Aug;21(4):729-736. doi: 10.1080/14737167.2020.1812387. Epub 2020 Sep 20. Expert Rev Pharmacoecon Outcomes Res. 2021. PMID: 32954900 Free article.

6

Assessing the value of human papillomavirus vaccination in Gavi-eligible low-income and middle-income countries.

Ochalek J, Abbas K, Claxton K, Jit M, Lomas J. Ochalek J, et al. BMJ Glob Health. 2020 Oct;5(10):e003006. doi: 10.1136/bmjgh-2020-003006. BMJ Glob Health. 2020. PMID: 33082132 Free PMC article.

7

Accounting for Timing when Assessing Health-Related Policies.

Claxton K, Asaria M, Chansa C, Jamison J, Lomas J, Ochalek J, Paulden M. Claxton K, et al. Among authors: ochalek j. J Benefit Cost Anal. 2019 Jan 26;10(Suppl 1):73-105. doi: 10.1017/bca.2018.29. J Benefit Cost Anal. 2019. PMID: 33282628 Free PMC article.

8

Accounting for country- and time-specific values in the economic evaluation of health-related projects relevant to low- and middle-income countries.

Lomas J, Claxton K, Ochalek J. Lomas J, et al. Among authors: ochalek j. Health Policy Plan. 2022 Jan 13;37(1):45-54. doi: 10.1093/heapol/czab104. Health Policy Plan. 2022. PMID: 34410385 Free PMC article.

9

Avoiding Opportunity Cost Neglect in Cost-Effectiveness Analysis for Health Technology Assessment.

Lomas J, Ochalek J, Faria R. Lomas J, et al. Among authors: ochalek j. Appl Health Econ Health Policy. 2022 Jan;20(1):13-18. doi: 10.1007/s40258-021-00679-9. Epub 2021 Sep 1. Appl Health Econ Health Policy. 2022. PMID: 34467474

10

Empirical Estimates of the Marginal Cost of Health Produced by a Healthcare System: Methodological Considerations from Country-Level Estimates.

Edney LC, Lomas J, Karnon J, Vallejo-Torres L, Stadhouders N, Siverskog J, Paulden M, Edoka IP, Ochalek J. Edney LC, et al. Among authors: ochalek j. Pharmacoeconomics. 2022 Jan;40(1):31-43. doi: 10.1007/s40273-021-01087-6. Epub 2021 Sep 29. Pharmacoeconomics. 2022. PMID: 34585359 Free PMC article. Review.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

28 results

Search Page